Loading
MapLight Therapeutics, Inc. Stock: price and insider trades · United States
US·Mcap US$445.7M
2 insiders bought €56.9M of shares over the last 90 days, the latest filed 18 Aug 2026.
MapLight Therapeutics, Inc.: what insiders have been doing
This page follows insider dealings at MapLight Therapeutics, Inc. as filed with SEC (Form 4). Between 18 October 2025 and 18 October 2026, 25 insiders published 150 filings.
Both sides are active: 8 purchases worth €57.3M and 83 sales worth €15.6M, from 4 insiders and 8 insiders respectively. The net balance comes to €41.6M on the buying side. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Those buying include 3 senior executives and 1 major shareholder. One trade stands out by size: a purchase of €43.4M from Catalyst4, Inc., disclosed on 18 August 2026, or 8.3% of market capitalisation.
The data flag 6 purchases as part of a group of insiders buying within 30 days of each other. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. The clock since the last published purchase (18 August 2026) now reads 61 days. The median gap between a trade and its publication by SEC (Form 4) is 2 days. US insiders must file a Form 4 within two business days of a trade. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.
Compared with its exchange (5,814 companies, median 19 filings), a count of 150 filings is above the norm. Since 2025, the database holds 8 purchases and 83 sales by insiders of the company. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists net income at -161.2 m USD.
Other companies in the same market with recent insider buying flagged by our signals: GameStop Corp. and Heico Corp. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
150
Thresholds
n/a
Buy Volume
€57M
8 ops. · all time
Sell Volume
€16M
83 ops. · all time
Who traded when
BuySaleJonathan Gillis14 sales
Erin Pennock Foff13 sales
Anatol Kreitzer12 sales
James Woodruff Lillie12 sales
Kristopher Hanson12 sales
Christopher A. Kroeger11 sales
+6 other insiders
Since the insiders bought
- -36.5%Entry US$12.15 · Close 16 Oct 2026 US$7.71
- -48.7%Entry US$15.02 · Close 16 Oct 2026 US$7.71
- +57.1%Entry US$18.30 · Close at T+90 US$28.75
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate MapLight Therapeutics, Inc. Strong Buy (bullish), based on 13 analysts. Average price target: US$26.54.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$8.02
Analyst consensus
13 analystsStrong buy
US$13.00Target US$26.54(+231%)US$43.00
Income statement
EBITDA-US$168.5M
Net income-US$161.2M0.0% margin
Valuation
PER (forward)-2.3x
P/Book1.0x
Balance sheet & cash
Market capUS$445.7M
Total debtUS$5.8M
Free Cash Flow-US$138.6M
Debt / Equity1%
Profitability & ownership
ROE-111.6%
ROA-67.1%
% insiders52.3%
% institutions48.8%
Last declaration on 16 October 2026
Declarations150 total
12,248 shares@ US$7.84Voting Common StockSEC:0002021238-26-000014:0
10,167 shares@ US$8.08Voting Common StockSEC:0001709954-26-000014:0
11,513 shares@ US$8.08Voting Common StockSEC:0001728746-26-000018:0
9,020 shares@ US$8.08Voting Common StockSEC:0001789970-26-000018:0
15,355 shares@ US$8.08Voting Common StockSEC:0002021233-26-000016:0
73,691 shares@ US$8.08Voting Common StockSEC:0001658918-26-000018:0
15,355 shares@ US$7.810.027% mcap2.7% of flowCommonSEC144:0001974158-26-000106
10,167 shares@ US$7.810.018% mcap2.0% of flowCommonSEC144:0001974158-26-000107
9,020 shares@ US$7.810.016% mcap3.3% of flowCommonSEC144:0001974158-26-000108
12,500 shares@ US$7.810.022% mcap3.6% of flowMapLight voting common stockSEC144:0001193125-26-422882
73,691 shares@ US$7.810.13% mcap3.7% of flowCommonSEC144:0001974158-26-000105
11,513 shares@ US$7.810.020% mcap3.1% of flowCommonSEC144:0001974158-26-000104
14,809 shares@ US$7.810.026% mcap15.1% of flowCommonSEC144:0001950047-26-010262
16,509 shares@ US$11.670.032% mcap9.0% of flowVoting Common StockSEC:0001789970-26-000016:0
16,509 shares@ US$12.080.033% mcap9.3% of flowCommonSEC144:0001974158-26-000102
13,360 shares0Voting Common StockSEC:0002021233-26-000014:0
6,020 shares0Voting Common StockSEC:0001709954-26-000012:0
2,222 shares0Voting Common StockSEC:0001709954-26-000012:1
7,730 shares0Voting Common StockSEC:0001789970-26-000014:0
6,020 shares0Voting Common StockSEC:0002021238-26-000012:0
23,145 shares0Voting Common StockSEC:0001658918-26-000016:0
7,730 shares0Voting Common StockSEC:0001728746-26-000016:0
4,400,000 shares@ US$11.388.26% mcap76.4% of flowVoting Common StockSEC:0001900201-26-000005:0
Canonical exit: 12 Nov 2026 (T+90)
22,082 shares@ US$12.540.046% mcap9.7% of flowVoting Common StockSEC:0001728746-26-000014:0
22,082 shares@ US$13.020.047% mcap10.0% of flowCommonSEC144:0001974158-26-000093
25 of 150 declarations
About MapLight Therapeutics, Inc.
MapLight Therapeutics, Inc. is a company focused on developing innovative therapies for the treatment of neurological diseases. It is listed on NASDAQ under the ticker XNAS.
Recent ranked signals on the same market
Purchases our model currently ranks for the recommendations list.
All recommendations
